Guggenheim Maintains Buy on Accolade, Lowers Price Target to $6
$ACCD
Business Services
Consumer Discretionary
Guggenheim analyst Sandy Draper maintains Accolade (NASDAQ:ACCD) with a Buy and lowers the price target from $13 to $6.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/28/2024 | $13.00 → $8.00 | Buy | Needham |
| 2/26/2024 | $16.00 | Outperform | Leerink Partners |
| 1/17/2024 | $16.00 → $14.00 | Neutral | DA Davidson |
| 1/3/2024 | $13.00 | Equal Weight | Barclays |
| 5/24/2023 | $16.50 | Neutral → Buy | BofA Securities |
| 4/12/2023 | $18.00 | Overweight | Stephens |
| 3/23/2023 | $16.00 | Neutral → Buy | Guggenheim |
| 2/9/2023 | $14.00 | Buy → Hold | Jefferies |
Guggenheim analyst Sandy Draper maintains Accolade (NASDAQ:ACCD) with a Buy and lowers the price target from $13 to $6.
Stifel analyst David Grossman maintains Accolade (NASDAQ:ACCD) with a Buy and lowers the price target from $13 to $8.
Truist Securities analyst Jailendra Singh maintains Accolade (NASDAQ:ACCD) with a Buy and lowers the price target from $14 to $9.
SC 13G/A - Accolade, Inc. (0001481646) (Subject)
SC 13G/A - Accolade, Inc. (0001481646) (Subject)
SC 13G - Accolade, Inc. (0001481646) (Subject)
Needham reiterated coverage of Accolade with a rating of Buy and set a new price target of $8.00 from $13.00 previously
Leerink Partners initiated coverage of Accolade with a rating of Outperform and set a new price target of $16.00
DA Davidson resumed coverage of Accolade with a rating of Neutral and set a new price target of $14.00 from $16.00 previously
SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced financial results for the fiscal second quarter ended August 31, 2024. "As we enter the second half of fiscal year 2025, we are well positioned to deliver our first full year of Adjusted EBITDA profitability and positive cash flow. Accolade is proving the scalability and profitability of a business model and strategy that is fundamentally designed to improve the lives of millions of people and their families. Our focus remains on solving the Physician Gap through a physician-led advocacy approach that engages the entire healthcare ecosystem and enables a better healthcare experience for our members," s
SEATTLE, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will release fiscal second quarter 2025 financial results on Tuesday, October 8, 2024 before market open. In conjunction, the company will host a conference call to review results at 8:00 a.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here (https://register.vevent.com/register/BI0b6b999c6e7b47fdb26d7e8a774df09f). Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. To Listen via Internet: The conference call can be accessed via a live a
SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will release fiscal first quarter 2025 financial results on Thursday, June 27, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here (https://register.vevent.com/register/BI651ad6356ede4b179553cca22ec02b2f). Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. To Listen via Internet: The conference call can be accessed via
SEATTLE, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will be presenting at the following upcoming investor events. A webcast will be available at ir.accolade.com and a replay will be available for 90 days. Stephens Annual Investment Conference | NASH2024 in Nashville on Wednesday, November 20 at 9:00 am CTCG MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 21. (1x1 meetings, no webcast)Piper Sandler 36th Annual Healthcare Conference in New York on Thursday, December 5 at 10:00 am ET. About Accolade, Inc. Accolade (NASDAQ:ACCD) is a Personalized Healthcare company that provides millions of people and the
Partnership will drive cost savings for customers while providing high-touch services that improve health outcomes to members with chronic kidney disease (CKD). SEATTLE, Oct. 15, 2024 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD) today announced that Renalogic, the recognized industry leader that manages the human and financial costs of chronic kidney disease (CKD) for self-insured employers and their members, will join the company's Trusted Partner Ecosystem, to offer its proven CKD risk management and dialysis cost containment solutions. Employers' health costs are expected
SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced financial results for the fiscal second quarter ended August 31, 2024. "As we enter the second half of fiscal year 2025, we are well positioned to deliver our first full year of Adjusted EBITDA profitability and positive cash flow. Accolade is proving the scalability and profitability of a business model and strategy that is fundamentally designed to improve the lives of millions of people and their families. Our focus remains on solving the Physician Gap through a physician-led advocacy approach that engages the entire healthcare ecosystem and enables a better healthcare experience for our members," s
144 - Accolade, Inc. (0001481646) (Subject)
144 - Accolade, Inc. (0001481646) (Subject)
144 - Accolade, Inc. (0001481646) (Subject)
Welcomes Dr. Connie Hwang as chief medical officer, creates roles of chief health officer and chief nursing officer SEATTLE, Sept. 18, 2023 /PRNewswire/ -- Accolade (NASDAQ:ACCD) announced the expansion of its care delivery team, strengthening the company's ability to streamline healthcare experiences through physician-led advocacy. Connie Hwang, MD, MPH, joins Accolade to lead population health strategies for employers and health plans. Led by Shantanu Nundy, MD, executive vice president, chief health officer, the care delivery leadership team includes Dr. Hwang, senior vice president, chief medical officer; James Wantuck, MD, senior vice president, associate chief medical officer and co-fo
With the addition of senior vice president and CISO, Kelli Burns, Accolade further elevates its focus on trusted, personalized relationships through exceptional information security for its members and customers SEATTLE, July 25, 2022 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD), the company that provides millions of people and their families with Personalized Healthcare, announced today that Kelli Burns has joined the organization as senior vice president, chief information security officer. Burns, a former consultant with Ernst & Young LLP (EY US) focused on cybersecurity en
Accolade welcomes executive vice president and chief human resources officer Jennifer Hanson to create an amazing employee experience for the company that partners with human resource leaders to deliver Personalized Healthcare SEATTLE, May 2, 2022 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD), the company that provides millions of people and their families with exceptional healthcare, announced today the appointment of Jennifer Hanson as chief human resources officer, executive vice president of people and culture, reporting to Accolade CEO, Rajeev Singh. Hanson will oversee
4 - Accolade, Inc. (0001481646) (Issuer)
4 - Accolade, Inc. (0001481646) (Issuer)
4 - Accolade, Inc. (0001481646) (Issuer)